Literature DB >> 21104208

Bone disorders in chronic liver diseases.

Bruce A Luxon1.   

Abstract

Bone disease is a major complication of chronic liver disease. Osteomalacia is quite uncommon despite low vitamin D levels in the majority of patients with cirrhosis. In contrast, osteoporosis is quite common, occurring in up to 50% of patients. Osteoporosis can result in spontaneous or low-impact fractures in patients with chronic liver diseases, adversely affecting morbidity, quality of life, and survival. The general biology of osteoporosis, including its pathogenesis, diagnostic tools, and rationale for treatment, have been determined largely empirically from studies of postmenopausal women with osteoporosis. Treatment regimens with modification of risk factors, use of vitamin D, and supplementation with calcium and bisphosphonates have been shown to be effective in select groups of patients with chronic liver diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21104208     DOI: 10.1007/s11894-010-0166-4

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  54 in total

1.  Guidelines on the management of osteoporosis associated with chronic liver disease.

Authors:  Jane D Collier; M Ninkovic; J E Compston
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

2.  A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis.

Authors:  A Floreani; F Zappala; W Fries; R Naccarato; M Plebani; A D'Angelo; M Chiaramonte
Journal:  J Clin Gastroenterol       Date:  1997-06       Impact factor: 3.062

3.  Prevalence and prediction of osteopenia in chronic liver disease.

Authors:  H L Bonkovsky; M Hawkins; K Steinberg; T Hersh; J T Galambos; J M Henderson; W J Millikan; J R Galloway
Journal:  Hepatology       Date:  1990-08       Impact factor: 17.425

4.  Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis.

Authors:  Núria Guañabens; Albert Parés; Inmaculada Ros; Llorenç Caballería; Francesca Pons; Sergi Vidal; Ana Monegal; Pilar Peris; Juan Rodés
Journal:  J Hepatol       Date:  2005-01-13       Impact factor: 25.083

Review 5.  Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment.

Authors:  Albert Parés; Núria Guañabens
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

6.  Bone mineral density among cirrhotic patients awaiting liver transplantation.

Authors:  Rana Paramvir Sokhi; Abhinandana Anantharaju; Ravi Kondaveeti; Steven D Creech; Khondker K Islam; David H Van Thiel
Journal:  Liver Transpl       Date:  2004-05       Impact factor: 5.799

7.  Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis.

Authors:  O Epstein; Y Kato; R Dick; S Sherlock
Journal:  Am J Clin Nutr       Date:  1982-09       Impact factor: 7.045

Review 8.  Bone disorders in chronic liver disease.

Authors:  Jane Collier
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

9.  Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice.

Authors:  C H Janes; E R Dickson; R Okazaki; S Bonde; A F McDonagh; B L Riggs
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

10.  Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?

Authors:  K D Lindor; C H Janes; J S Crippin; R A Jorgensen; E R Dickson
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

View more
  21 in total

Review 1.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

2.  Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.

Authors:  Germán López-Larramona; Alfredo J Lucendo; Sonia González-Castillo; José M Tenias
Journal:  World J Hepatol       Date:  2011-12-27

3.  Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients.

Authors:  Michael Mello; Rick A Weideman; Bertis B Little; Mark W Weideman; Byron Cryer; Geri R Brown
Journal:  Dig Dis Sci       Date:  2012-05-22       Impact factor: 3.199

Review 4.  Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review.

Authors:  Du Hwan Kim; Duk Hyun Sung; Yong Ki Min
Journal:  J Bone Miner Metab       Date:  2012-09-14       Impact factor: 2.626

5.  Children and adolescents with cystic fibrosis display moderate bone microarchitecture abnormalities: data from high-resolution peripheral quantitative computed tomography.

Authors:  C Braun; J Bacchetta; P Braillon; R Chapurlat; J Drai; P Reix
Journal:  Osteoporos Int       Date:  2017-08-09       Impact factor: 4.507

6.  Assessment of bone metabolism biomarkers in serum and saliva of cirrhotic patients.

Authors:  Jefferson Rocha Tenório; Nathália Tuany Duarte; Natália Silva Andrade; Mariana Lobo Bergamini; Ana Carolina Mamana; Paulo Henrique Braz-Silva; Karem L Ortega
Journal:  Clin Oral Investig       Date:  2021-09-07       Impact factor: 3.573

Review 7.  Vitamin D supplementation for chronic liver diseases in adults.

Authors:  Milica Bjelakovic; Dimitrinka Nikolova; Goran Bjelakovic; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2021-08-25

8.  Reduced Serum IGF-1 Associated With Hepatic Osteodystrophy Is a Main Determinant of Low Cortical but Not Trabecular Bone Mass.

Authors:  Zhongbo Liu; Tianzhen Han; Haim Werner; Clifford J Rosen; Mitchell B Schaffler; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2017-11-06       Impact factor: 6.741

Review 9.  Osteoporosis in liver disease: pathogenesis and management.

Authors:  Gabriela Handzlik-Orlik; Michał Holecki; Krzysztof Wilczyński; Jan Duława
Journal:  Ther Adv Endocrinol Metab       Date:  2016-04-06       Impact factor: 3.565

10.  Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected Mediterranean subjects.

Authors:  Valentina Li Vecchi; Maurizio Soresi; Lydia Giannitrapani; Giovanni Mazzola; Sara La Sala; Fabio Tramuto; Giuseppe Caruso; Claudia Colomba; Pasquale Mansueto; Simona Madonia; Giuseppe Montalto; Paola Di Carlo
Journal:  BMC Infect Dis       Date:  2012-08-15       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.